# A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05759897` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05759897](<https://clinicaltrials.gov/study/NCT05759897>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05759897

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

## Technical summary

Registry record NCT05759897. Randomized; double masking; primary purpose other. Start 2023-02-28 (anticipated); primary completion 2023-12-21 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose other
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT05759897, source copy `cardio:ctgov-nct05759897-2023-03-08`, retrieved 2026-10-26)
- Planned start: 2023-02-28 (anticipated) (ClinicalTrials.gov record NCT05759897, source copy `cardio:ctgov-nct05759897-2023-03-08`, retrieved 2026-10-26)
- Primary completion: 2023-12-21 (anticipated) (ClinicalTrials.gov record NCT05759897, source copy `cardio:ctgov-nct05759897-2023-03-08`, retrieved 2026-10-26)
- Completion: 2024-01-04 (anticipated) (ClinicalTrials.gov record NCT05759897, source copy `cardio:ctgov-nct05759897-2023-03-08`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05759897-2023-03-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): HRS-7535
- Intervention (Drug): Placebo
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial (`cardio:pubmed-42234428`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d0a1388ba1ddf3784ed8649003a2d389ac6e48a025a785d6c3468435688a9f46
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
